Related Experiment Video
Updated: May 27, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Identification of cytotoxic drugs that selectively target tumor cells with MYC overexpression
Anna Frenzel1, Hanna Zirath, Marina Vita
1Department of Microbiology Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden.
Abstract:
Expression of MYC is deregulated in a wide range of human cancers, and is often associated with aggressive disease and poorly differentiated tumor cells. Identification of compounds with selectivity for cells overexpressing MYC would hence be beneficial for the treatment of these tumors. For this purpose we used cell lines with conditional MYCN or c-MYC expression, to screen a library of 80 conventional cytotoxic compounds for their ability to reduce tumor cell viability and/or growth in a MYC dependent way. We found that 25% of the studied compounds induced apoptosis and/or inhibited proliferation in a MYC-specific manner. The activities of the majority of these were enhanced both by c-MYC or MYCN over-expression. Interestingly, these compounds were acting on distinct cellular targets, including microtubules (paclitaxel, podophyllotoxin, vinblastine) and topoisomerases (10-hydroxycamptothecin, camptothecin, daunorubicin, doxorubicin, etoposide) as well as DNA, RNA and protein synthesis and turnover (anisomycin, aphidicholin, gliotoxin, MG132, methotrexate, mitomycin C). Our data indicate that MYC overexpression sensitizes cells to disruption of specific pathways and that in most cases c-MYC and MYCN overexpression have similar effects on the responses to cytotoxic compounds. Treatment of the cells with topoisomerase I inhibitors led to down-regulation of MYC protein levels, while doxorubicin and the small molecule MYRA-A was found to disrupt MYC-Max interaction. We conclude that the MYC pathway is only targeted by a subset of conventional cytotoxic drugs currently used in the clinic. Elucidating the mechanisms underlying their specificity towards MYC may be of importance for optimizing treatment of tumors with MYC deregulation. Our data also underscores that MYC is an attractive target for novel therapies and that cellular screenings of chemical libraries can be a powerful tool for identifying compounds with a desired biological activity.
Insights
MYC overexpression in cancer cells sensitizes them to specific cytotoxic drugs, including those targeting microtubules and topoisomerases. This finding highlights MYC as a potential therapeutic target for various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- MYC oncoprotein deregulation is common in many human cancers, correlating with aggressive disease and poor differentiation.
- Targeting MYC-overexpressing cancer cells with specific compounds offers a potential therapeutic strategy.
Purpose of the Study:
- To identify conventional cytotoxic compounds that selectively reduce viability and/or growth in cells overexpressing MYC (MYCN or c-MYC).
- To investigate the mechanisms by which MYC overexpression influences cellular responses to cytotoxic agents.
Main Methods:
- Screening of 80 conventional cytotoxic compounds using cell lines with conditional MYCN or c-MYC expression.
- Assessing compound-induced apoptosis and proliferation inhibition in a MYC-dependent manner.
- Analyzing compound mechanisms of action, including effects on microtubules, topoisomerases, and nucleic acid/protein synthesis.
Main Results:
- Approximately 25% of screened compounds demonstrated MYC-specific activity, with effects often enhanced by MYC or MYCN overexpression.
- Active compounds targeted diverse cellular pathways, including microtubule dynamics, topoisomerase activity, and DNA/RNA/protein synthesis.
- Topoisomerase I inhibitors reduced MYC protein levels, while doxorubicin and MYRA-A disrupted MYC-Max interaction.
Conclusions:
- MYC overexpression sensitizes cancer cells to specific cytotoxic drug classes, indicating MYC pathway involvement in drug response.
- A subset of conventional cytotoxic drugs targets the MYC pathway, suggesting potential for optimizing cancer therapy.
- Cellular screening of chemical libraries is effective for identifying compounds with MYC-specific biological activity, supporting MYC as a therapeutic target.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Induced Pluripotent Stem Cells
Somatic cells are...
Mitogens and the Cell Cycle

